Summary
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.
The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101069333 |
| Start date: | 01-06-2022 |
| End date: | 30-11-2023 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
Status
CLOSEDCall topic
ERC-2022-POC1Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
